|
69 Companies |
|
87 Products |
|
87 Products |
|
71 Mechanisms of Action |
|
3 Trials |
|
597 News |
|
| 12345678910111213» |
- | colchicine / Generic mfg.
Enrollment change, Trial completion date, Trial termination: Heat Intolerance in the Group of FMF Patients (clinicaltrials.gov) - Apr 4, 2024
P=N/A, N=7, Terminated, Sponsor: Sheba Medical Center
N=15 --> 7 | Trial completion date: Dec 2025 --> Mar 2024 | Enrolling by invitation --> Terminated; unable to recruit patients
- | colchicine / Generic mfg.
Trial completion date, Trial primary completion date: Heat Intolerance in the Group of FMF Patients (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=15, Enrolling by invitation, Sponsor: Sheba Medical Center
N=15 --> 7 | Trial completion date: Dec 2025 --> Mar 2024 | Enrolling by invitation --> Terminated; unable to recruit patients Trial completion date: Dec 2018 --> Dec 2025 | Trial primary completion date: Aug 2018 --> Aug 2025
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Potential Research Study Participant Registry (clinicaltrials.gov) - Feb 16, 2019
P=N/A, N=265, Completed, Sponsor: University of California, Davis
Trial completion date: Dec 2018 --> Dec 2025 | Trial primary completion date: Aug 2018 --> Aug 2025 Recruiting --> Completed | N=200 --> 265 | Trial completion date: Jan 2025 --> Sep 2018 | Trial primary completion date: Jan 2025 --> Sep 2018
- | NN1213 / Novo Nordisk
Trial completion: Evaluation of an Integrated Care Project (clinicaltrials.gov) - Feb 15, 2019
P=N/A, N=3960, Completed, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed | N=200 --> 265 | Trial completion date: Jan 2025 --> Sep 2018 | Trial primary completion date: Jan 2025 --> Sep 2018 Enrolling by invitation --> Completed
- | NN1213 / Novo Nordisk
Biomarker, Trial termination, Biopsy: GNE-AD: A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal (clinicaltrials.gov) - Jan 24, 2019
P4, N=11, Terminated, Sponsor: University of California, San Francisco
Enrolling by invitation --> Completed Completed --> Terminated; Unable to meet the study's recruitment goals
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: LUVIA: The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (clinicaltrials.gov) - Dec 28, 2018
P=N/A, N=10, Completed, Sponsor: Johns Hopkins University
Completed --> Terminated; Unable to meet the study's recruitment goals Recruiting --> Completed | N=28 --> 10 | Trial completion date: Dec 2018 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018
- | NN1213 / Novo Nordisk
Trial primary completion date: IPCRR: International Pachyonychia Congenita Research Registry (clinicaltrials.gov) - Nov 21, 2018
P=N/A, N=2000, Recruiting, Sponsor: Pachyonychia Congenita Project
Recruiting --> Completed | N=28 --> 10 | Trial completion date: Dec 2018 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018 Trial primary completion date: Dec 2058 --> Dec 2030
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date: Assessing Risk of Food Insecurity Within Households of Children With Food Allergy (clinicaltrials.gov) - Oct 15, 2018
P=N/A, N=650, Completed, Sponsor: Arkansas Children's Hospital Research Institute
Trial primary completion date: Dec 2058 --> Dec 2030 Enrolling by invitation --> Completed | Trial completion date: Dec 2017 --> Aug 2018
- | Phase classification, HEOR, Cost effectiveness: Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Sep 11, 2018
P4, N=39, Completed, Sponsor: Wake Forest University Health Sciences
Enrolling by invitation --> Completed | Trial completion date: Dec 2017 --> Aug 2018 Phase classification: P=N/A --> P4
- | Phase classification: Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Sep 7, 2018
P2, N=10, Completed, Sponsor: Wake Forest University
Phase classification: P=N/A --> P4 Phase classification: P=N/A --> P2
- ||| Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Enrollment change: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Jun 3, 2018
P2b, N=204, Completed, Sponsor: MedImmune LLC
Phase classification: P=N/A --> P2 N=306 --> 204
- | Phase classification, Enrollment change: Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) - Apr 6, 2018
P, N=929, Completed, Sponsor: National Institute on Aging (NIA)
N=306 --> 204 Phase classification: P=N/A --> P | N=1335 --> 929
- |||| timapiprant (OC000459) / Chiesi
Trial completion: Effect of OC000459 on Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Mar 26, 2018
P2, N=142, Completed, Sponsor: Atopix Therapeutics, Ltd.
Phase classification: P=N/A --> P | N=1335 --> 929 Active, not recruiting --> Completed
- Phase classification: Porphozym in the Treatment of Acute Attacks in AIP (clinicaltrials.gov) - Mar 9, 2018
P2/3, N=36, Completed, Sponsor: Zymenex A/S
Active, not recruiting --> Completed Phase classification: P2 --> P2/3
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Registry for the Atopic Dermatitis Research Network (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=3386, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P2 --> P2/3 Recruiting --> Completed | N=2600 --> 3386 | Trial primary completion date: Feb 2020 --> Feb 2018 | Trial completion date: Feb 2020 --> Feb 2018
- | Reimbursement, Trial primary completion date: Evaluation of an Integrated Care Project (clinicaltrials.gov) - Jan 30, 2018
P=N/A, N=3960, Enrolling by invitation, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed | N=2600 --> 3386 | Trial primary completion date: Feb 2020 --> Feb 2018 | Trial completion date: Feb 2020 --> Feb 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial completion: Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=126, Completed, Sponsor: Nestl
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- | tacrolimus topical / Generic mfg.
Trial completion, Adherence: Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit (clinicaltrials.gov) - Dec 19, 2017
P4, N=30, Completed, Sponsor: Wake Forest University
Active, not recruiting --> Completed Recruiting --> Completed
- | Stelara (ustekinumab) / J&J
Trial completion, Trial primary completion date: Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis (clinicaltrials.gov) - Dec 19, 2017
P2, N=32, Completed, Sponsor: Rockefeller University
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2015 | Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2015 | Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2015
- | Trial primary completion date: LUVIA: The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism (clinicaltrials.gov) - Dec 14, 2017
P=N/A, N=28, Recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2015 | Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2015 | Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2015 Trial primary completion date: Sep 2017 --> Dec 2018
- | triamcinolone acetonide topical / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Adherence: Pediatric Atopic Dermatitis (AD) Internet Survey (clinicaltrials.gov) - Nov 1, 2017
P=N/A, N=0, Withdrawn, Sponsor: Wake Forest University
Trial primary completion date: Sep 2017 --> Dec 2018 N=40 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Oct 2017 --> Oct 2014
- | Humira (adalimumab) / AbbVie
Trial completion: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Oct 18, 2017
P2, N=11, Completed, Sponsor: Assistance Publique - H
N=40 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Oct 2017 --> Oct 2014 Active, not recruiting --> Completed
- |||| Dupixent (dupilumab) / Sanofi, Regeneron
Trial primary completion date: CHRONOS: Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Oct 17, 2017
P3, N=740, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Aug 2015
- | pirfenidone / Generic mfg.
Trial completion: Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome (clinicaltrials.gov) - Oct 15, 2017
P2, N=35, Completed, Sponsor: William Gahl, M.D.
Trial primary completion date: Nov 2015 --> Aug 2015 Active, not recruiting --> Completed
- | colchicine / Generic mfg.
Enrollment change: Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission (clinicaltrials.gov) - Oct 11, 2017
P=N/A, N=0, Withdrawn, Sponsor: Sheba Medical Center
Active, not recruiting --> Completed N=80 --> 0
- ||| Trial completion, Trial primary completion date: ECP-015: Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=150, Completed, Sponsor: Edimer Pharmaceuticals
N=80 --> 0 Active, not recruiting --> Completed | Trial primary completion date: Oct 2019 --> Dec 2016
- | colchicine / Generic mfg.
Trial primary completion date: Heat Intolerance in the Group of FMF Patients (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=15, Enrolling by invitation, Sponsor: Sheba Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Oct 2019 --> Dec 2016 Trial primary completion date: Feb 2010 --> Aug 2018
- | Trial completion, Enrollment change: Bleach Bath Treatment of Adults With Atopic Dermatitis (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=58, Completed, Sponsor: University of Rochester
Trial primary completion date: Feb 2010 --> Aug 2018 Recruiting --> Completed | N=30 --> 58
- | Phase classification: Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Jun 23, 2017
P2, N=7, Completed, Sponsor: Vanderbilt University Medical Center
Recruiting --> Completed | N=30 --> 58 Phase classification: P=N/A --> P2
- | Amevive (alefacept) / Astellas
Trial termination: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=3, Terminated, Sponsor: Emory University
Phase classification: P=N/A --> P2 Suspended --> Terminated; drug company is no longer making the drug
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA (clinicaltrials.gov) - May 31, 2017
P2/3, N=36, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Suspended --> Terminated; drug company is no longer making the drug Active, not recruiting --> Completed
- | Phase classification: Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis (clinicaltrials.gov) - May 30, 2017
P=N/A, N=183, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed Phase classification: P2 --> P=N/A
- || Enrollment change: To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children (clinicaltrials.gov) - May 23, 2017
P=N/A, N=82, Completed, Sponsor: Johnson & Johnson Consumer and Personal Products Worldwide
Phase classification: P2 --> P=N/A N=108 --> 82
- |||| Ilaris (canakinumab) / Novartis
Trial primary completion date: CLUSTER: Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers (clinicaltrials.gov) - May 18, 2017
P3, N=204, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=108 --> 82 Trial primary completion date: Jun 2017 --> Aug 2015
- Trial completion, Trial initiation date, Trial primary completion date: Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis (clinicaltrials.gov) - May 1, 2017
P=N/A, N=10, Completed, Sponsor: Wake Forest University
Trial primary completion date: Jun 2017 --> Aug 2015 Recruiting --> Completed | Initiation date: Nov 2011 --> Feb 2012 | Trial primary completion date: Dec 2016 --> Aug 2013
- | hydrocortisone butyrate / Generic mfg.
Trial completion, Adherence: Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid (clinicaltrials.gov) - Apr 20, 2017
P4, N=26, Completed, Sponsor: Wake Forest University
Recruiting --> Completed | Initiation date: Nov 2011 --> Feb 2012 | Trial primary completion date: Dec 2016 --> Aug 2013 Active, not recruiting --> Completed
- | triamcinolone acetonide topical / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial primary completion date, IO biomarker, Biopsy: GNE-AD: A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal (clinicaltrials.gov) - Apr 12, 2017
P4, N=11, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Recruiting --> Completed | N=15 --> 11 | Trial primary completion date: Jan 2017 --> Apr 2017
- | pimecrolimus topical / Generic mfg.
Phase classification, Biopsy: Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=28, Completed, Sponsor: National Jewish Health
Recruiting --> Completed | N=15 --> 11 | Trial primary completion date: Jan 2017 --> Apr 2017 Phase classification: P4 --> P=N/A
- | Enrollment change, Trial withdrawal: Study to Examine the Benefits of Fabric Made With Lyocell/Chitosan/Ceramide in the Treatment of Children With Mild to Moderate Eczema (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Phase classification: P4 --> P=N/A N=60 --> 0 | Not yet recruiting --> Withdrawn
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Phase classification: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (clinicaltrials.gov) - Mar 21, 2017
P2b, N=306, Completed, Sponsor: MedImmune LLC
N=60 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P2 --> P2b
- | triamcinolone acetonide topical / Generic mfg.
Trial primary completion date, Adherence: Pediatric Atopic Dermatitis (AD) Internet Survey (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=40, Active, not recruiting, Sponsor: Wake Forest University
Phase classification: P2 --> P2b Trial primary completion date: Oct 2016 --> Oct 2017
- | Reimbursement, Trial primary completion date: Evaluation of an Integrated Care Project (clinicaltrials.gov) - Mar 9, 2017
P=N/A, N=3960, Enrolling by invitation, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Nov 2015 --> Dec 2017
- betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment (clinicaltrials.gov) - Feb 16, 2017
P3, N=17, Terminated, Sponsor: EMS
Trial primary completion date: Nov 2015 --> Dec 2017 N=140 --> 17 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Aug 2016; By sponsor decision due to difficulty of recruitment
- Orfadin (nitisinone) / Astellas, SOBI
Trial primary completion date: Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) - Jan 31, 2017
P1/2, N=5, Active, not recruiting, Sponsor: National Eye Institute (NEI)
N=140 --> 17 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Aug 2016; By sponsor decision due to difficulty of recruitment Trial primary completion date: Dec 2017 --> Jul 2016
- ||| AIMab7195 / Nestle
Trial completion, Trial primary completion date: Safety and Tolerability of XmAb (clinicaltrials.gov) - Jan 24, 2017
P1, N=72, Completed, Sponsor: Xencor, Inc.
Trial primary completion date: Dec 2017 --> Jul 2016 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Sep 2015
- | SB011 / Sterna Biologicals
Trial completion: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema (clinicaltrials.gov) - Jan 13, 2017
P2a, N=25, Completed, Sponsor: Sterna Biologicals GmbH & Co. KG
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Sep 2015 Active, not recruiting --> Completed
- Enrollment open, Enrollment change, Trial primary completion date: Bleach Bath Treatment of Adults With Atopic Dermatitis (clinicaltrials.gov) - Dec 29, 2016
P=N/A, N=30, Recruiting, Sponsor: University of Rochester
Active, not recruiting --> Completed Completed --> Recruiting | N=46 --> 30 | Trial primary completion date: Apr 2016 --> May 2017
- Trial completion: GenTAC: National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=3706, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Completed --> Recruiting | N=46 --> 30 | Trial primary completion date: Apr 2016 --> May 2017 Active, not recruiting --> Completed
- Enrollment closed: Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis (clinicaltrials.gov) - Nov 28, 2016
P=N/A, N=126, Active, not recruiting, Sponsor: Nestl
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | SB011 / Sterna Biologicals
Enrollment closed, Trial primary completion date: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema (clinicaltrials.gov) - Nov 8, 2016
P2a, N=26, Active, not recruiting, Sponsor: Sterna Biologicals GmbH & Co. KG
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2016